Skip to main content
Skip to footer

Sudip Kar

Senior Manager, Life Sciences, TCS


  • M&A activity in the pharma industry increased in 2022, with a sizable uptick in the number of buyouts and an increase in the average deal size compared to 2021. 
  • Strict pharma regulations make managing M&As even more challenging. 
  • A few Industry 4.0 enablers and approaches can help navigate complexities and manage mergers and acquisitions efficiently.